Biogen Gets FDA, EMA Approval to Study Higher Dose Regimen of Spinal Muscular Atrophy Treatment

MT Newswires Live01-23

Biogen (BIIB) announced Thursday that the US Food and Drug Administration has accepted its supplemental new drug application and that the European Medicines Agency has validated the application for a higher dose regimen of its experimental drug, nusinersen, for spinal muscular atrophy.

The company said it would study the efficacy of a higher dose regimen, including two 50 mg doses given 14 days apart and a maintenance dose of 28 mg every four months, compared to the currently approved regimen.

Nusinersen, marketed as Spinraza, is available in over 71 countries at the approved 12 mg dose, it added.

Biogen licensed the global rights to develop and commercialize Spinraza from Ionis Pharmaceuticals (IONS).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment